Comparative effectiveness of GLP-1 RAs and other glucose-lowering therapies among Medicare Advantage beneficiaries with T2D and ASCVD
Among MA beneficiaries with T2D and ASCVD, risk of CV outcomes was lower with OW GLP-1 RAs, particularly semaglutide, vs ONIGLTs including SGLT2is.
Authors
- Xi Tan (ORCID: https://orcid.org/0000-0002-2409-5927)
- Cynthia Gutierrez (ORCID: https://orcid.org/0000-0002-8528-8554)
- Lin Xie (ORCID: https://orcid.org/0000-0002-8850-6764)
- Joanna Harton (ORCID: https://orcid.org/0000-0002-7626-9466)
- Adam de Havenon (ORCID: https://orcid.org/0000-0001-8178-8597)
- Caroline Swift (ORCID: https://orcid.org/0000-0003-3192-1200)
- Chalak Muhammad
- Yuanjie Liang (ORCID: https://orcid.org/0000-0003-4566-0865)
Institutions
- MIND Research Institute (US)
- Novo Nordisk (United Kingdom) (GB)
- Genesis Research Institute (JP)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1080/03007995.2025.2577762
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29